Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Akrivis Technologies has signed an agreement with United States Biological Corporation (USBiological) to co-develop, manufacture, promote and sell new products and services for research use based on Akrivis' Z-TECT technology platform.
Subscribe to our email newsletter
Z-TECT platform is designed by adapting elements of nanotechnology with molecular detection and immunology to aid the research field.
Z-TECT will help in the early detection of cancer biomarkers in vitro, according to Akrivis.
The technology with the capabality of imaging millimeter-size micro-lesions in animal models will also detect cancer in vivo at much lower levels of growth.
Akrivis Technologies CEO Joel Berniacof said the agreement provides Akrivis with USBiological’s US and international sales and distribution channels for the commercialization of its Z-TECT ultrasensitive detection platform for research use.
"In addition, Akrivis and USBiological will co-develop new ultrasensitive kits based onUSBiological’s extensive catalog of biomolecular targets, biomarkers and antibodies, covering the oncology, CNS, cardiovascular, inflammation and auto-immune therapeutic areas," Berniacof added.
USBiological president Warren Shore said the agreement provides the research community with ultrasensitive reagents and kits for a variety of immunoassay formats which include ELISA, chemiluminescence, Western blot, immunohistochemistry, immunofluorescence, flow cytometry and radioimmunoassays.